Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy
复制标题
DOI：
10.1007/s10637-020-00983-6
复制
发表时间：
2020-08-11
影响因子：
3.4
通讯作者：
Hoshino, Tomoaki
中科院分区：
文献类型：
--
作者：
Ishii, Hidenobu;Azuma, Koichi;Hoshino, Tomoaki
尽管免疫检查点抑制剂改善了小细胞肺癌（SCLC）患者的生存率，但其在全身化疗后复发的SCLC患者中的疗效尚不清楚。本回顾性研究旨在研究atezolizumab联合卡铂和依托泊苷治疗既往接受过含铂化疗的SCLC患者的效用。我们回顾性筛选了连续8例接受atezolizumab联合卡铂和依托泊苷的小细胞肺癌患者。我们评估了这种治疗的疗效及其与程序性细胞死亡配体1（PD-L1）表达的相关性。3例和5例患者分别对一线铂类化疗敏感和难治性复发。总有效率为37.5%，疾病控制率为75.0%。中位无进展生存期为4个月。在3例达到临床缓解的患者中，2例患者在一线铂类化疗中出现难治性复发。无患者表现出PD-L1表达。Atezolizumab联合卡铂和依托泊苷治疗对敏感和难治性复发的SCLC患者有效，可能是既往接受过铂类化疗的SCLC患者的二线治疗选择。
Although immune checkpoint inhibitors have improved the survival of small cell lung cancer (SCLC) patients, their efficacy in SCLC patients who relapsed after systemic chemotherapy is unclear. This retrospective study aimed to investigate the utility of treatment with atezolizumab plus carboplatin and etoposide in SCLC patients previously treated with platinum-based chemotherapy. We retrospectively screened consecutive eight SCLC patients who received atezolizumab plus carboplatin and etoposide after platinum-based chemotherapy. We evaluated the efficacy of this treatment and its association with programmed cell death-ligand 1 (PD-L1) expression. Three and five patients had sensitive relapse and refractory relapse for first-line platinum-based chemotherapy, respectively. The overall response rate and disease control rate was 37.5% and 75.0%, respectively. Median progression-free survival was 4.0 months. Out of three patients who achieved clinical response, two patients had refractory relapse for first-line platinum-based chemotherapy. No patient exhibited PD-L1 expression. Atezolizumab plus carboplatin and etoposide therapy was effective in SCLC patients with sensitive and refractory relapse and might be a second-line treatment option for SCLC patients previously treated with platinum-based chemotherapy.